Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

102.0K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
102.0K
Sanger Sequencing01:57

Sanger Sequencing

780.5K
DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
780.5K
Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

4.3K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
4.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Human Virome01:26

Human Virome

42
The human body harbors a vast and diverse viral community known as the human virome. The virome includes bacteriophages that infect bacteria, and eukaryotic viruses that infect human cells. Transient dietary and environmental viruses also contribute to this dynamic ecosystem. Estimates suggest the human body may contain on the order of 10¹³ viral particles, though abundance varies widely by body site and detection method.Comprehensive characterization of the virome has become possible...
42
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.

Blood·2022
Same author

The outcome of older adults with classic Hodgkin lymphoma in British Columbia.

Blood advances·2022
Same author

Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma.

The Journal of clinical investigation·2022
Same author

A gene expression-based model predicts outcome in children with intermediate-risk classical Hodgkin lymphoma.

Blood·2021
Same author

Outcome of limited-stage nodular lymphocyte-predominant Hodgkin lymphoma and the impact of a PET-adapted approach.

Blood advances·2021
Same author

MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma.

Haematologica·2021
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.7K

Summary and future directions.

Randy D Gascoyne1

  • 1Departments of Pathology & Lymphoid Cancer Research, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC Canada.

Seminars in Hematology
|March 26, 2015
PubMed
Summary
This summary is machine-generated.

Developing predictive biomarkers is crucial for advancing precision medicine in diffuse large B-cell lymphoma (DLBCL). These biomarkers will guide the deployment of novel targeted therapies and improve patient outcomes beyond current prognostic markers.

More Related Videos

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:50

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

1.2K
Measuring and Manipulating Functionally Specific Neural Pathways in the Human Motor System with Transcranial Magnetic Stimulation
09:52

Measuring and Manipulating Functionally Specific Neural Pathways in the Human Motor System with Transcranial Magnetic Stimulation

Published on: February 23, 2020

10.0K

Related Experiment Videos

Last Updated: Apr 15, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.7K
Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study
07:50

Global and Current Research Trends of Single-Cell Sequencing in Cancer: A Bibliometric and Visualization Study

Published on: April 18, 2025

1.2K
Measuring and Manipulating Functionally Specific Neural Pathways in the Human Motor System with Transcranial Magnetic Stimulation
09:52

Measuring and Manipulating Functionally Specific Neural Pathways in the Human Motor System with Transcranial Magnetic Stimulation

Published on: February 23, 2020

10.0K

Area of Science:

  • Hematological Oncology
  • Cancer Genomics
  • Clinical Research Design

Background:

  • Diffuse large B-cell lymphoma (DLBCL) understanding is mature, enabling a new phase in treatment.
  • Current treatment paradigms require advancement towards precision medicine.
  • A significant unmet need exists for guiding novel targeted therapies.

Purpose of the Study:

  • To propose a roadmap for clinical research in DLBCL.
  • To emphasize the urgent need for robust biomarkers.
  • To transition from prognostic to predictive biomarkers for therapy selection.

Main Methods:

  • Leveraging the current understanding of DLBCL's genetic landscape.
  • Developing biomarkers to identify patients likely to fail current treatments (e.g., R-CHOP).
  • Informing molecular correlates of treatment failure for future clinical trials.

Main Results:

  • Current understanding of DLBCL biology is sufficient for a new research phase.
  • Robust biomarkers are essential for interpreting Phase III clinical trial results.
  • Biomarkers can define patients who will not benefit from R-CHOP.

Conclusions:

  • A strategic roadmap for DLBCL clinical research is necessary.
  • Predictive biomarkers are key to advancing precision medicine in DLBCL.
  • Future therapy selection should be guided by molecular correlates of treatment response.